Literature DB >> 26884866

Yes associated protein is a poor prognostic factor in well-differentiated lung adenocarcinoma.

Mi Hyun Kim1, Young Keum Kim2, Dong Hoon Shin2, Hyun Jeong Lee2, Nari Shin2, Arong Kim2, Jung Hee Lee2, Kyung Un Choi2, Jee Yeon Kim2, Chang Hun Lee2, Mee Young Sol2.   

Abstract

The Hippo pathway is a highly conserved potent regulator of cell growth and apoptosis including large tumor suppressor (LATS) and Yes-associated protein (YAP). LATS has been regarded as a tumor suppressor gene and YAP as either of a tumor suppressor gene or an oncogene. We investigated their expression in lung adenocarcinoma. YAP and LATS protein expression was assessed in 167 surgically resected lung adenocarcinomas and compared with clinicopathologic factors. Disease free survival and overall survival were also evaluated. YAP expression was noted in cytoplasm (48 cases; 28.7%), nuclear (34; 20.4%) and both locations (4; 2.4%). The nuclear expression was typically observed in well differentiated adenocarcinoma. LATS was expressed in cytoplasm when its signal is weak. Perinuclear expression of LATS was observed when it is strongly expressed. While cytoplasmic and nuclear YAP expressions were inversely related. In well differentiated adenocarcinoma patients, YAP nuclear expression was related with more frequent relapse. Both of nuclear YAP and LATS expression were more frequently observed in well differentiated adenocarcinoma. Furthermore, YAP expression exhibited more frequent relapse in well differentiated adenocarcinoma group. We suggest that YAP may act as an oncogene and predict poorer prognosis in well differentiated lung adenocarcinoma.

Entities:  

Keywords:  LATS; Lung; YAP; adenocarcinoma; hippo pathway

Mesh:

Substances:

Year:  2015        PMID: 26884866      PMCID: PMC4730079     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  17 in total

Review 1.  LATS tumor suppressor: a new governor of cellular homeostasis.

Authors:  Stacy Visser; Xiaolong Yang
Journal:  Cell Cycle       Date:  2010-10-20       Impact factor: 4.534

2.  Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer.

Authors:  Yang Wang; Qianze Dong; Qingfu Zhang; Zixuan Li; Enhua Wang; Xueshan Qiu
Journal:  Cancer Sci       Date:  2010-01-23       Impact factor: 6.716

3.  The hippo pathway effector Yap controls patterning and differentiation of airway epithelial progenitors.

Authors:  John E Mahoney; Munemasa Mori; Aleksander D Szymaniak; Xaralabos Varelas; Wellington V Cardoso
Journal:  Dev Cell       Date:  2014-07-17       Impact factor: 12.270

4.  Bronchioloalveolar carcinoma of the lung: recurrences and survival in patients with stage I disease.

Authors:  O S Breathnach; D J Kwiatkowski; D M Finkelstein; J Godleski; D J Sugarbaker; B E Johnson; S Mentzer
Journal:  J Thorac Cardiovasc Surg       Date:  2001-01       Impact factor: 5.209

5.  Expression of Yes-associated protein in common solid tumors.

Authors:  Angela A Steinhardt; Mariana F Gayyed; Alison P Klein; Jixin Dong; Anirban Maitra; Duojia Pan; Elizabeth A Montgomery; Robert A Anders
Journal:  Hum Pathol       Date:  2008-08-13       Impact factor: 3.466

6.  Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene.

Authors:  Dawang Zhou; Claudius Conrad; Fan Xia; Ji-Sun Park; Bernhard Payer; Yi Yin; Gregory Y Lauwers; Wolfgang Thasler; Jeannie T Lee; Joseph Avruch; Nabeel Bardeesy
Journal:  Cancer Cell       Date:  2009-11-06       Impact factor: 31.743

Review 7.  Filling out the Hippo pathway.

Authors:  Leslie J Saucedo; Bruce A Edgar
Journal:  Nat Rev Mol Cell Biol       Date:  2007-08       Impact factor: 94.444

8.  Why do pathological stage IA lung adenocarcinomas vary from prognosis?: a clinicopathologic study of 176 patients with pathological stage IA lung adenocarcinoma based on the IASLC/ATS/ERS classification.

Authors:  Jie Zhang; Jie Wu; Qiang Tan; Lei Zhu; Wen Gao
Journal:  J Thorac Oncol       Date:  2013-09       Impact factor: 15.609

Review 9.  Metastasis: from dissemination to organ-specific colonization.

Authors:  Don X Nguyen; Paula D Bos; Joan Massagué
Journal:  Nat Rev Cancer       Date:  2009-04       Impact factor: 60.716

10.  LATS2 tumour specific mutations and down-regulation of the gene in non-small cell carcinoma.

Authors:  Mojca Strazisar; Vid Mlakar; Damjan Glavac
Journal:  Lung Cancer       Date:  2008-11-12       Impact factor: 5.705

View more
  14 in total

Review 1.  Long Non-coding RNA ZFPM2-AS1: A Novel Biomarker in the Pathogenesis of Human Cancers.

Authors:  Gabriel B K Sasa; Cheng Xuan; Guoliang Lyu; Xianfeng Ding; Fang Meiyu
Journal:  Mol Biotechnol       Date:  2022-01-31       Impact factor: 2.695

2.  NEDD4 promotes cell growth and motility in hepatocellular carcinoma.

Authors:  Hailun Zheng; Xiquan Ke; Dapeng Li; Qiangwu Wang; Jianchao Wang; Xiaoyang Liu; Min Deng; Xiaojing Deng; Yongju Xue; Yu Zhu; Qizhi Wang
Journal:  Cell Cycle       Date:  2018-04-10       Impact factor: 4.534

Review 3.  A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy.

Authors:  Masahiro Shibata; Kendall Ham; Mohammad Obaidul Hoque
Journal:  Int J Cancer       Date:  2018-07-24       Impact factor: 7.396

4.  Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer.

Authors:  Sho Nambara; Takaaki Masuda; Miki Nishio; Shotaro Kuramitsu; Taro Tobo; Yushi Ogawa; Qingjiang Hu; Tomohiro Iguchi; Yousuke Kuroda; Shuhei Ito; Hidetoshi Eguchi; Keishi Sugimachi; Hiroshi Saeki; Eiji Oki; Yoshihiko Maehara; Akira Suzuki; Koshi Mimori
Journal:  Oncotarget       Date:  2017-11-21

5.  PTEN lipid phosphatase inactivation links the hippo and PI3K/Akt pathways to induce gastric tumorigenesis.

Authors:  Wenting Xu; Zhen Yang; Chuan Xie; Yin Zhu; Xu Shu; Zhe Zhang; Nianshuang Li; Na Chai; Song Zhang; Kaichun Wu; Yongzhan Nie; Nonghua Lu
Journal:  J Exp Clin Cancer Res       Date:  2018-08-22

6.  Prognostic significance of nuclear Yes-associated protein 1 in patients with nonsmall cell lung cancer: A systematic review and meta-analysis.

Authors:  Lingling Zhu; Guangzhi Ma; Jiewei Liu; Yunfu Deng; Qiang Wu; Wenjie Chen; Qinghua Zhou
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

7.  CADM1 associates with Hippo pathway core kinases; membranous co-expression of CADM1 and LATS2 in lung tumors predicts good prognosis.

Authors:  Takeshi Ito; Atsuko Nakamura; Ichidai Tanaka; Yumi Tsuboi; Teppei Morikawa; Jun Nakajima; Daiya Takai; Masashi Fukayama; Yoshitaka Sekido; Toshiro Niki; Daisuke Matsubara; Yoshinori Murakami
Journal:  Cancer Sci       Date:  2019-05-29       Impact factor: 6.716

8.  LncRNA ZFPM2-AS1 promotes lung adenocarcinoma progression by interacting with UPF1 to destabilize ZFPM2.

Authors:  Shuhua Han; Dandan Cao; Jun Sha; Xiaoli Zhu; Dongqin Chen
Journal:  Mol Oncol       Date:  2020-02-20       Impact factor: 6.603

9.  Up-regulation of long non-coding RNA SPRY4-IT1 promotes tumor cell migration and invasion in lung adenocarcinoma.

Authors:  Xia Zhang; Qingyan Chi; Zhenhua Zhao
Journal:  Oncotarget       Date:  2017-04-07

10.  Activating Hippo Pathway via Rassf1 by Ursolic Acid Suppresses the Tumorigenesis of Gastric Cancer.

Authors:  Seong-Hun Kim; Hua Jin; Ruo Yu Meng; Da-Yeah Kim; Yu Chuan Liu; Ok Hee Chai; Byung Hyun Park; Soo Mi Kim
Journal:  Int J Mol Sci       Date:  2019-09-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.